NCT07030478View on ClinicalTrials.gov

A Study to Evaluate the Safety and Tolerability of EP0089

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

190

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

June 30, 2029

Conditions

Solid CancersSolid Tumours

Interventions

DRUG

EP0089-101

EP0089 will be initially administered by intravenous (IV) infusion once every 2 weeks (Q2W)

Sponsors

Lead Sponsor

Ellipses Pharma

All Listed Sponsors

lead

Ellipses Pharma

INDUSTRY

NCT07030478 - A Study to Evaluate the Safety and Tolerability of EP0089 | Biotech Hunter | Biotech Hunter